Pilar Tavera-Rodríguez

Pilar Tavera-Rodríguez

Auto-generated profile, based on publicly available information

Pilar Tavera-Rodríguez

Instituto Nacional de Salud, Bogotá 111321, Colombia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
DÁDiego Alejandro Álvarez-Díaz
Diego Alejandro Álvarez-Díaz
AMAna Muñoz
Ana Muñoz
PTPilar Tavera-Rodríguez
Pilar Tavera-Rodríguez
MHMaría T. Herrera-Sepúlveda
María T. Herrera-Sepúlveda
HRHector Alejandro Ruiz-Moreno
Hector Alejandro Ruiz-Moreno
MMMarcela Mercado-Reyes
Marcela Mercado-Reyes
Global surveillance programs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are showing the emergence of variants with mutations in the spike protein. Genomic and laboratory surveillance are important to determine if these variants may be more infectious or less susceptible to antiviral treatments and vaccine-induced antibodies. Three of the most predominant SARS-CoV-2 variants in Colombia during the epidemiological peaks of 2021 were isolated: Mu, a variant of interest; Gamma, a variant of concern; B.1.111, which lacks genetic markers associated with greater virulence. Microneutralization assays were performed by incubating 120 mean tissue culture infectious doses (TCID50) of each SARS-CoV-2 isolate with five two-fold serial dilutions of sera from 31 BNT162b2-vaccinated volunteers. The mean neutralization titer (MN50) was calculated by the Reed–Muench method. At the end of August, Mu represented 49% of coronavirus disease 2019 (COVID-19) cases in Colombia, followed by 25% of Gamma. In contrast, B.1.111 became almost undetectable. The evaluation of neutralizing antibodies suggests that patients vaccinated with BNT162b2 generate neutralizing antibody titers against the Mu variant at significantly lower concentrations relative to B.1.111 and Gamma. This study shows the importance of continuing surveillance programs of emerging variants, as well as the need to evaluate the neutralizing antibody response induced by other vaccines.

26 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
Jeadran N. Malagón-RojasJeadran N. Malagón-Rojas
Jeadran N. Malagón-Rojas
MMMarcela Mercado-Reyes
Marcela Mercado-Reyes
YTYesith G. Toloza-Pérez
Yesith G. Toloza-Pérez
MGMarisol Galindo
Marisol Galindo
RPRuth M. Palma
Ruth M. Palma
MOMartha Lucía Ospina-Martínez
Martha Lucía Ospina-Martínez
To mitigate the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccines have been rapidly developed and introduced in many countries. In Colombia, the population was vaccinated with four vaccines. Therefore, this research aimed to determine the ability of the vaccines introduced in the National Vaccination Plan to prevent SARS-CoV-2 infection and induce seroconversion and sought to investigate the longevity of antibodies in the blood. We conducted a prospective, nonprobabilistic, consecutive cross-sectional cohort study in a population with access to vaccination with CoronaVac, Ad26.COV2.S, AZD1222, and BNT162b2 from March 2021 to March 2022. The study included 1327 vaccinated people. A plurality of participants were vaccinated with BNT162b2 (36.1%; n = 480), followed by Ad26.COV2.S (26.9%; n = 358), CoronaVac (24%; n = 331), and AZD1222 (11.9%; n = 158). The crude seroprevalence on day zero varied between 18.1% and 57.8%. Participants who received BNT162b2 had a lower risk of SARS-CoV-2 infection than those who received the other vaccines. Participants who were immunized with BNT162b2 and AZD1222 had a higher probability of losing reactivity on day 210 after receiving the vaccine.

15 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
DÁDiego Alejandro Álvarez-Díaz
Diego Alejandro Álvarez-Díaz
AMAna Muñoz
Ana Muñoz
MHMaría T. Herrera-Sepúlveda
María T. Herrera-Sepúlveda
PTPilar Tavera-Rodríguez
Pilar Tavera-Rodríguez
KLKatherine Laiton-Donato
Katherine Laiton-Donato
MMMarcela Mercado-Reyes
Marcela Mercado-Reyes
Background By March 2022, around 34 million people in Colombia had received a complete scheme of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) including, mRNA-based vaccines, viral vectored coronavirus vaccines, or the inactivated whole virus vaccine. However, as several SARS-CoV-2 variants of concern (VOC) and interest (VOI) co-circulate in the country, determining the resistance level to vaccine-elicited neutralizing antibodies (nAbs) is useful to improve the efficacy of COVID-19 vaccination programs. Methods Microneutralization assays with the most prevalent SARS-CoV-2 lineages in Colombia during 2020-2021 were performed using serum samples from immunologically naïve individuals between 9 and 13 weeks after receiving complete regimens of CoronaVac, BNT162b2, ChAdOx1, or Ad26.COV2.S. The mean neutralization titer (MN50) was calculated by the Reed–Muench method and used to determine differences in vaccine-elicited nAbs against the SARS-CoV-2 lineages B.1.111, P.1 (Gamma), B.1.621 (Mu), and AY.25.1 (Delta). Results The most administered vaccines in the country, BNT162b2 and CoronaVac, elicited significantly different nAb responses against Mu, as the GMTs were 75.7 and 5.9-fold lower relative to the control lineage (B.1.111), while for Delta were 15.8 and 1.1-fold lower, respectively. In contrast, nAb responses against Mu and Delta were comparable between ChAd0×1-s and Ad26.COV2.S as the GMTs remained around 5 to 7-fold lower relative to B.1.111. Conclusions The emergence of SARS-CoV-2 variants in Colombia with a significant capacity to escape from vaccine-elicited nAbs indicates that a booster dose is highly recommended. Furthermore, other non-pharmacological measures should be retained in the vaccinated population.

1 June 2022 in medRxiv
Verified
Preprint
Open access
PDF file
PTPilar Tavera-Rodríguez
Pilar Tavera-Rodríguez
JBJuliana Barbosa-Ramírez
Juliana Barbosa-Ramírez
ABAndrea Bermúdez-Forero
Andrea Bermúdez-Forero
DPDiego Prada-Cardozo
Diego Prada-Cardozo
JRJhonnatan Reales-González
Jhonnatan Reales-González
MMMarcela Mercado-Reyes
Marcela Mercado-Reyes
The healthcare workers are considered as a high-risk group for infection with SARS-CoV-2, so they were included in the first stage of the National Plan for Vaccination against COVID-19 in Colombia. An ongoing prospective cohort study to evaluate immune response to vaccination included 490 workers from health institutions in Bogotá, Colombia, vaccinated between March and June 2021 with BNT162b2 (Pfizer-BioNtech). Multiple samples were collected during a follow-up period of 6 months after immunization. We report cases of asymptomatic and symptomatic SARS-CoV-2 infections detected in this cohort. For each participant demographic data, vaccination dates, results for SARS-CoV-2 RT-PCR, and detection of antibody (IgG) tests during the follow-up period were collected. SARS-CoV-2 infection was detected in 38 (7.7 %) volunteers. Of these, 81.6% had a positive RT-PCR for SARS-CoV-2, and 18.4% were confirmed by detection of IgG anti-SARS-CoV-2 nucleoprotein; 76.3% of infections occurred after 7 days of second dose. A total of 57.9% of the cases were asymptomatic. No hospitalizations or deaths were registered. When infection occurred, 81.6% of infected participants had presence of IgG anti-S antibodies. In 12 samples in which genomic characterization was achieved, 83.4% corresponded to the variant Mu, 8.3% Gamma, and 8.3% Delta. All findings agree with other reports in different studies that show the benefit of COVID-19 vaccines, protecting specially against severe disease but not against infection or re-infection.